
Revolution Medicines (RVMD) Stock Forecast & Price Target
Revolution Medicines (RVMD) Analyst Ratings
Bulls say
Revolution Medicines is a clinical-stage precision oncology company with a promising pipeline of RAS(ON) Inhibitors and a successful track record in structure-based drug discovery. With a high probability of approval for key pipeline candidates and a discounted cash flow valuation methodology, the stock appears undervalued compared to peers in similar stages of development. Risks include clinical setbacks, competition, and dilutive financing, but the potential for long-term market leadership and appreciation in share price make Revolution Medicines an attractive investment opportunity.
Bears say
Revolution Medicines is a clinical stage pharmaceutical company with a heavy focus on developing therapies for RAS-addicted cancers. While they possess unique technologies and capabilities, their near-term revenue forecast is conservative, and their recent combo data does not provide enough justification for their current valuation. Additionally, there is still a significant degree of uncertainty surrounding the success of their ongoing Phase 3 trials. Overall, the low short-term potential for significant revenue growth and high risk in their current pipeline make us wary of investing at this time.
This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.
Revolution Medicines (RVMD) Analyst Forecast & Price Prediction
Start investing in Revolution Medicines (RVMD)
Order type
Buy in
Order amount
Est. shares
0 shares